Additionally, the same study indicated significant increases in GH even at a dosage of 10mcg/kg [14]
In addition, the SOUL trial (NCT03914326) is a currently ongoing CVOT to evaluate the hypothesis that oral semaglutide lowers the risk of cardiovascular events in T2DM patients at high risk for CVD
doi: 10.3389/fmolb.2025.1724944 Received 14 October 2025 Revised 18 November 2025 Accepted 30 November 2025 Published 18 December 2025 Volume 12 - 2025 Edited by Maria Barile, University of Bari Aldo Moro, Italy Reviewed by Anna Maria Giudetti, University of Salento, Italy Maria Tolomeo, National Research Council (CNR), Italy Updates Copyright 2025 Schrder, Jalilvand, Kahl, Kaiser and Liebau
& Todd Alexander, R
Ethics declarations Ethics Approval All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards
This is a particular point of risk as over- or under- dilution will lead to a product that is stronger or weaker than expected or intended, leading to the dose of the product injected being higher or lower than expected
